

# PMR Operational Report

|                             |                             |   |          |
|-----------------------------|-----------------------------|---|----------|
| <b>Operation Number</b>     | AR-L1142                    | <b>Chief of Operations Validation Date</b>    | 04/19/17 |
| <b>Year- PMR Cycle</b>      | Second period Jan-Dec 2016  | <b>Division Chief Validation Date</b>         | 04/19/17 |
| <b>Last Update</b>          | 04/12/17                    | <b>Country Representative Validation Date</b> | 04/23/17 |
| <b>PMR Validation Stage</b> | Validated by Representative |   |          |

## Basic Data

### Operation Profile

|                           |  |   |                                 |
|---------------------------|--|---|---------------------------------|
| <b>Operation Name</b>     | Multiphase Primary Health Care Program for Managing Chronic Non-communicable Dis | <b>Loan Number</b>                      | 2788/OC-AR                      |
| <b>Executing Agency</b>   | MINISTERIO DE SALUD  | <b>Sector/Subsector</b>                 | SA-SER - HEALTH-HEALTH SERVICES |
| <b>Team Leader</b>        | SANCHEZ,MARIO ALBERTO  | <b>Overall Stage</b>                    | Fully Disbursed                 |
| <b>Operation Type</b>     | Loan Operation   | <b>Country</b>                          | ARGENTINA                       |
| <b>Lending Instrument</b> | Investment Loan  | <b>Convergence related Operation(s)</b> |                                 |
| <b>Borrower</b>           | Republica Argentina  |   |                                 |


## Environmental and Social Safeguards

|   |   |  |    |
|---|---|--|----|
| <b>Impacts Category</b>                         | C | <b>Was/Were the objective(s) of this operation reformulated?</b> | NO |
| <b>Safeguard Performance Rating</b>             |   | <b>Date of approval</b>  |    |
| <b>Safeguard Performance Rating - Rationale</b> |   |  |    |

## Financial Data

| Item              | Total Cost and Source |                    |                   |                        |                     | Available Funds (US\$) |                      |                |                    |
|-------------------|-----------------------|--------------------|-------------------|------------------------|---------------------|------------------------|----------------------|----------------|--------------------|
|                   | Original IDB          | Current IDB        | Local Counterpart | Co-Financing / Country | Total Original Cost | Current IDB            | Disb. Amount to Date | % Disb         | Undisbursed Amount |
| AR-L1142          | 150,000,000           | 150,000,000        | 50,000,000        | 0                      | 200,000,000         | 150,000,000            | 150,000,000          | 100.00%        | 0                  |
| <b>Aggregated</b> | <b>150,000,000</b>    | <b>150,000,000</b> | <b>50,000,000</b> | <b>0</b>               | <b>200,000,000</b>  | <b>150,000,000</b>     | <b>150,000,000</b>   | <b>100.00%</b> | <b>0</b>           |

## Expense Categories by Loan Contract (cumulative values)



Please note that the Overall Stage represents the stage of the operation at the time of this report's publication, which might not necessarily match the stage of the operation during the PMR Cycle to which the report pertains. Please also note that inactive indicators and outputs are not displayed; totals in the actual cost table may not match the sum of the cost of the outputs displayed, due to the cost of inactive outputs.

## PMR Operational Report

### RESULTS MATRIX

### IMPACTS

No information available for this section

## PMR Operational Report

### RESULTS MATRIX

#### OUTCOMES

**Outcome Nbr. 1:** Personas clasificadas por Riesgo Cardiovascular Global

**Observation:** La línea de base es el valor esperado del indicador para el programa AR-L1020

| Indicator  |  | Unit of Measure   | Baseline      | Baseline Year |      | 2015      | 2016       | 2017      | EOP 2017   |
|--|--|-------------------|---------------|---------------|------|-----------|------------|-----------|------------|
| 1.1  | Personas de 40 a 64 años de edad, con cobertura pública exclusiva, clasificadas por Riesgo Cardiovascular Global | Beneficiaries (#) | 295660.0      | 2014          | P    |           | 490,236.00 |           | 490,236.00 |
|  |  |                   |               |               | P(a) |           | 47,987.00  | 20,194.00 | 418,485.00 |
|  |  |                   |               |               | A    | 74,838.00 | 45,393.00  |           |            |
| Details  |  |                   |               |               |      |           |            |           |            |
| Means of verification: Auditorías médicas externas |  |                   |               |               |      |           |            |           |            |
| Pro-Gender   |  | No                | Pro-Ethnicity |               | No   |           |            |           |            |

| Indicator                                       |  | Unit of Measure   | Baseline      | Baseline Year |      | 2015      | 2016       | 2017     | EOP 2017   |
|---|--|-------------------|---------------|---------------|------|-----------|------------|----------|------------|
| 1.2   | Hombres de 40 a 64, con cobertura pública exclusiva, que son clasificados por Riesgo Cardiovascular Global | Beneficiaries (#) | 100806.0      | 2014          | P    |           | 244,157.00 |          | 244,157.00 |
|   |  |                   |               |               | P(a) |           | 38,250.00  | 6,866.00 | 162,662.00 |
|   |  |                   |               |               | A    | 23,606.00 | 16,442.00  |          |            |
| Details   |  |                   |               |               |      |           |            |          |            |
| Means of verification: Auditoría médica externa |  |                   |               |               |      |           |            |          |            |
| Pro-Gender                                      |  | No                | Pro-Ethnicity |               | No   |           |            |          |            |

**Outcome Nbr. 2:** Personas con riesgo cardiovascular alto bien seguidas

**Observation:** La línea de base corresponde al valor esperado para el indicador de AR-L1020

| Indicator   |  | Unit of Measure | Baseline      | Baseline Year |      | 2015      | 2016      | 2017   | EOP 2017   |
|---|--|-----------------|---------------|---------------|------|-----------|-----------|--------|------------|
| 2.1   | Personas clasificadas con riesgo cardiovascular global mayor a 10% que alguna vez realizaron una consulta de seguimiento posterior a su clasificación. | Personas        | 52689.0       | 2014          | P    |           | 91,656.00 |        | 91,656.00  |
|   |  |                 |               |               | P(a) |           | 38,250.00 | 363.00 | 162,662.00 |
|   |  |                 |               |               | A    | 39,173.00 | 49,274.00 |        |            |
| Details   |  |                 |               |               |      |           |           |        |            |
| Means of verification: Auditoría médica externa   |  |                 |               |               |      |           |           |        |            |
| Observations: Este indicador será modificado a principios de 2014 para reflejar que el cuidado de pacientes es un proceso continuo. El indicador pasará de ser un stock a un flujo anual. |  |                 |               |               |      |           |           |        |            |
| Pro-Gender  |  | No              | Pro-Ethnicity |               | No   |           |           |        |            |

**Outcome Nbr. 3:** Población con cobertura pública exclusiva empadronada

**Observation:** La línea de base corresponde al valor esperado del indicador para AR-L1020.

| Indicator | Unit of | Baseline | Baseline |  | 2015 | 2016 | 2017 | EOP 2017 |
|-----------|---------|----------|----------|--|------|------|------|----------|
|-----------|---------|----------|----------|--|------|------|------|----------|

## PMR Operational Report

### RESULTS MATRIX

#### OUTCOMES

|   |  | Measure  |               | Year |      |            |              |            |              |
|---|--|----------|---------------|------|------|------------|--------------|------------|--------------|
| 3.1   | Población con cobertura pública exclusiva mayor a 6 años empadronada | Personas | 2734158.0     | 2014 | P    |            | 3,750,000.00 |            | 3,750,000.00 |
|   |  |          |               |      | P(a) |            | 0.00         | 103,666.00 | 3,750,000.00 |
|   |  |          |               |      | A    | 597,360.00 | 249,177.00   |            |              |
| Details   |  |          |               |      |      |            |              |            |              |
| Means of verification: Auditoría Médica externa |  |          |               |      |      |            |              |            |              |
| Pro-Gender                                      |  | No       | Pro-Ethnicity |      | No   |            |              |            |              |

**Outcome Nbr. 4:** Consultantes a los que les prescribieron medicamentos que los reciben de REMEDIAR

**Observation:**

| Indicator  |  | Unit of Measure | Baseline      | Baseline Year |      | 2015 | 2016  | 2017 | EOP 2017 |
|--|--|-----------------|---------------|---------------|------|------|-------|------|----------|
| 4.1  | Porcentaje de consultantes en centros de atención primaria con cobertura pública exclusiva que les prescribieron medicamentos que los recibieron de REMEDIAR | Porcentaje      | 87.0          | 2014          | P    |      | 95.00 |      | 95.00    |
|  |  |                 |               |               | P(a) |      | 90.00 | 0.00 | 90.00    |
|  |  |                 |               |               | A    |      | 88.00 |      |          |
| Details  |  |                 |               |               |      |      |       |      |          |
| Means of verification: Encuesta de consultantes a CAPS |  |                 |               |               |      |      |       |      |          |
| Pro-Gender   |  | No              | Pro-Ethnicity |               | No   |      |       |      |          |

## RESULTS MATRIX

## OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

## Component Nbr. 1 Proyectos Provinciales de Fortalecimiento de Servicios de Salud

|     | Output   | Unit of Measure    |      | PHYSICAL PROGRESS |          | FINANCIAL PROGRESS |            |
|-----|--|--------------------|------|-------------------|----------|--------------------|------------|
|     |  |                    |      | 2016              | EOP 2017 | 2016               | EOP 2017   |
| 1.1 | Proyectos jurisdiccionales bajo la modalidad "Redes 2" aprobados.  | Provincias         | P    |                   | 15       |                    | 2,000,000  |
|     |  |                    | P(a) | 2                 | 24       | 1,341,515          | 3,840,236  |
|     |  |                    | A    | 1                 | 23       | 1,127,052          | 3,832,525  |
| 1.2 | Provincias ejecutando proyectos provinciales "Redes 2" por año.  | Provincias         | P    |                   | 15       |                    | 37,500,000 |
|     |  |                    | P(a) | 24                | 76       | 20,455,811         | 34,501,033 |
|     |  |                    | A    | 23                | 52       | 17,213,685         | 27,310,918 |
| 1.3 | Personal sanitario capacitado.   | Personal sanitario | P    |                   | 3,000    |                    | 1,000,000  |
|     |  |                    | P(a) | 3,405             | 10,664   | 423,958            | 1,612,017  |
|     |  |                    | A    | 3,827             | 7,774    | 378,697            | 1,500,091  |
| 1.4 | Informe de evaluación del piloto de cáncer colorrectal finalizado.   | Informe            | P    |                   | 1        |                    | 2,100,000  |
|     |  |                    | P(a) | 1                 | 2        | 820,042            | 1,525,477  |
|     |  |                    | A    | 0                 | 1        | 130,166            | 1,164,739  |
| 1.5 | Evaluación cuali-cuantitativa de los factores condicionantes a la aplicación y adherencia a las normas de evaluación de Riesgo Cardiovascular Global en efectores del Primer Nivel de Atención finalizada. | Informe            | P    |                   | 1        |                    | 100,000    |
|     |  |                    | P(a) | 0                 | 2        | 0                  | 0          |
|     |  |                    | A    | 0                 | 2        | 0                  | 0          |
| 1.6 | Estudios de caso de estrategias innovadoras provinciales evaluadas.  | Estudios           | P    |                   | 10       |                    | 300,000    |
|     |  |                    | P(a) | 10                | 12       | 122,755            | 160,280    |
|     |  |                    | A    | 0                 | 0        | 27,018             | 145,735    |

## Component Nbr. 2 Provisión de servicios estratégicos

|     | Output   | Unit of Measure                      |      | PHYSICAL PROGRESS |             | FINANCIAL PROGRESS |             |
|-----|--|--------------------------------------|------|-------------------|-------------|--------------------|-------------|
|     |  |                                      |      | 2016              | EOP 2017    | 2016               | EOP 2017    |
| 2.1 | Tratamientos con medicamentos esenciales distribuidos.   | Tratamientos                         | P    |                   | 92,877,880  |                    | 126,540,000 |
|     |  |                                      | P(a) | 0                 | 111,885,799 | 0                  | 135,137,694 |
|     |  |                                      | A    | 0                 | 111,885,799 | 286,324            | 135,137,694 |
| 2.2 | Unidades de dispensa de medicamentos equipadas para la mejora en la gestión clínica.   | Unidades de dispensa de medicamentos | P    |                   | 1,360       |                    | 8,000,000   |
|     |  |                                      | P(a) | 643               | 1,481       | 0                  | 1,396,908   |
|     |  |                                      | A    | 340               | 1,481       | 120,311            | 1,396,908   |
| 2.3 | Nuevos tratamientos (estatinas y amlodipina) distribuidos.   | Tratamientos                         | P    |                   | 101,250     |                    | 5,000,000   |
|     |  |                                      | P(a) | 0                 | 513,149     | 0                  | 0           |
|     |  |                                      | A    | 0                 | 513,149     | 0                  | 0           |
| 2.4 | Informe de identificación de procesos críticos para conseguir la certificación de procesos de Remediar aprobado por el Ministerio de Salud de la Nación. | Informe                              | P    |                   | 1           |                    | 100,000     |
|     |  |                                      | P(a) | 0                 | 1           | 0                  | 52,310      |
|     |  |                                      | A    | 0                 | 1           | 0                  | 52,310      |
| 2.5 | Personal sanitario capacitado en uso racional de medicamentos.   | Personal sanitario                   | P    |                   | 4,000       |                    | 1,050,000   |
|     |  |                                      | P(a) | 4,113             | 8,830       | 0                  | 1,571,565   |
|     |  |                                      | A    | 2,026             | 8,830       | 22,254             | 1,571,565   |
| 2.6 | Estudios y evaluaciones para el Programa Remediar finalizados.   | Estudios                             | P    |                   | 5           |                    | 310,000     |
|     |  |                                      | P(a) | 6                 | 6           | 0                  | 8,570       |
|     |  |                                      | A    | 0                 | 6           | 0                  | 8,570       |

## RESULTS MATRIX

### OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

#### Component Nbr. 3 Consolidación de sistemas de información de salud pública

|     | Output   | Unit of Measure                          |      | PHYSICAL PROGRESS |          | FINANCIAL PROGRESS |           |
|-----|--|--|------|-------------------|----------|--------------------|-----------|
|     |  |  |      | 2016              | EOP 2017 | 2016               | EOP 2017  |
| 3.1 | Informe sobre Sistemas de Informacion a nivel de Centros de Atencion Primaria de la Salud. | Informe                                  | P    |                   | 1        |                    | 3,000,000 |
|     |  |  | P(a) | 0                 | 1        | 0                  | 0         |
|     |  |  | A    | 0                 | 1        | 0                  | 0         |
| 3.2 | Centros de atención primaria de la salud informatizados.                                   | Centros de atención primaria de la salud | P    |                   | 1,000    |                    | 2,000,000 |
|     |  |  | P(a) | 618               | 1,476    | 811,507            | 2,398,119 |
|     |  |  | A    | 582               | 1,476    | 872,180            | 2,328,670 |
| 3.3 | Hospitales que reportan al Registro Integral de Tumores de la Argentina.                   | Hospitales                               | P    |                   | 10       |                    | 1,000,000 |
|     |  |  | P(a) | 0                 | 24       | 275,511            | 1,286,234 |
|     |  |  | A    | 0                 | 24       | 351,057            | 1,097,954 |
| 3.4 | Provincias cuyos hospitales han sido incorporados al Sistema de Información de Tamizaje.   | Hospitales                               | P    |                   | 7        |                    | 1,000,000 |
|     |  |  | P(a) | 0                 | 12       | 890,422            | 3,465,519 |
|     |  |  | A    | 0                 | 12       | 1,161,038          | 2,767,333 |

#### Other Cost

|  |                |      |  |  |           |            |
|--|----------------|------|--|--|-----------|------------|
|  | Administración | P    |  |  |           | 6,500,000  |
|  |                | P(a) |  |  | 1,585,853 | 12,544,038 |
|  |                | A    |  |  | 2,893,089 | 10,902,398 |
|  | Comisiones     | P    |  |  |           | 500,000    |
|  |                | P(a) |  |  | 0         | 500,000    |
|  |                | A    |  |  | 500,000   | 500,000    |
|  | Imprevistos    | P    |  |  |           | 2,000,000  |
|  |                | P(a) |  |  | 0         | 0          |
|  |                | A    |  |  | 0         | 0          |

#### Total Cost

|  |            |      |  |  |            |             |
|--|------------|------|--|--|------------|-------------|
|  | Total Cost | P    |  |  |            | 200,000,000 |
|  |            | P(a) |  |  | 26,727,374 | 200,000,000 |
|  |            | A    |  |  | 25,082,871 | 189,717,410 |

### CHANGES TO THE MATRIX

No information available for this section